Skip to content

DMT: all studies

Page 14 of 160: studies 131 to 140 of 1,593, newest first. Back to the DMT overview

Research

Investigating the Synergistic Neuroprotective Effects of Plant-Derived Antioxidants and the Psychedelic N,N-Dimethyltryptamine in Alzheimer's Disease Therapy.

Cells June 19, 2025 Júlia Jarne-Ferrer, Mercè Pallàs, Christian Griñán-Ferré et al. 2 citations

Alzheimer's disease (AD) is a chronic and complex neurodegenerative disorder characterized by progressive cognitive decline, memory loss, and irreversible impairment of brain functions. The etiology of AD is multifactorial, involving a complex interplay of genetic, environmental, and physiological factors, including the aggregation of amyloid-β (Aβ) and oxidative stress (OS). The role of OS in...

Enhancing mindfulness and compassion through an ayahuasca-inspired formulation containing N,N-DMT and harmine: A randomized controlled trial in healthy subjects.

Journal of Psychopharmacology June 19, 2025 Helena Aicher, Ilhui A Wicki, Daniel Meling et al. 2 citations

Mindfulness and compassion are therapeutically relevant and can be increased through different forms of meditation practices. However, meditation practice needs time and commitment. These resources are often limited in patients with mood disorders. Therefore, efficacious remedies that increase mindfulness and compassion could provide therapeutic options. This study aimed to investigate the...

Safety, tolerability and subjective effects of vaporized N,N-Dimethyltryptamine: A randomized double-blind clinical trial.

European Neuropsychopharmacology June 17, 2025 Isabel Wießner, Marcelo Falchi-Carvalho, Sophie Laborde et al. 7 citations

Vaporized N,N-Dimethyltryptamine (DMT) has a short duration and simple application, prompting this technique as a new approach for psychedelics' clinical use. Building on our initial dose-ascending studies and addressing potential confounding effects of dosing order, this study is the first to evaluate inhaled DMT in a randomized, placebo-controlled, double-blind design. Given DMT's therapeutic...

DOI: 10.1016/j.euroneuro.2025.06.002 (opens in new tab) Full text (opens in new tab) Psychedelic therapy N,N-Dimethyltryptamine Placebo-controlled study Psychedelics +17

Treating War Trauma with Ibogaine and 5-MEO-DMT

June 16, 2025 María José Polanco, Mark D. Black

This chapter details the therapy protocols involving ibogaine utilized at The Mission Within (https://missionwithin.org) in Baja California, Mexico, as described by its founder and research director, Dr. Martin Polanco, along with psychedelic preparation/integration counselor and therapeutic facilitator, Dr. Mia Black. The chapter describes: Their personal development as ibogaine therapists and...

Immunomodulatory and behavioral effects of ayahuasca and N, N-dimethyltryptamine in a rat model of lipopolysaccharide-induced depression.

Metabolic Brain Disease June 11, 2025 Daniel do Nascimento Sousa, Monique de Azevedo, Maria Lucília Santos et al. 5 citations

Ayahuasca (Aya) is an Amazonian beverage traditionally used as medicine by Indigenous people in South America to treat various illnesses and have shown a potential to treat depression. This study aimed to investigate the antidepressant effects of fluoxetine, Aya and N, N dimethyl tryptamine (DMT), a component of the beverage, focusing on the modulation of inflammatory serum cytokine profiles...

Safety and tolerability of NN-dimethyltryptamine (DMT) in healthy volunteers and Major Depressive Disorder (MDD) patients: A systematic review of early-phase clinical trials.

Progress in Neuro-Psychopharmacology and Biological Psychiatry June 7, 2025 Damian Swieczkowski, Aleksander Kwaśny, Wiesław Jerzy Cubała 5 citations

Treatment-resistant depression (TRD) remains a challenge, with many patients unresponsive to standard antidepressants. NN-dimethyltryptamine (DMT), a fast-acting psychedelic, offers potential benefits due to its rapid onset and short duration. This review, registered with the Open Science Framework (DOI: 10.17605/OSF.IO/6D9WC), summarizes the safety and tolerability of DMT in early-phase...

DOI: 10.1016/j.pnpbp.2025.111419 (opens in new tab) Full text (opens in new tab) Nn-Dimethyltryptamine DMT Systematic review Treatment resistant depression Psychedelics hallucinogens +4

Request for Proposals - Exploring expanded consciousness and endogenous DMT

June 5, 2025 Tyler C. Diorio

Request for Proposals - Exploring expanded consciousness and endogenous DMT Sponsor: DMT Quest Aim of Funding This funding seeks to advance scientific understanding of consciousness, human potential, and the mechanisms underlying expanded awareness. Eligible research may investigate endogenous N,N-dimethyltryptamine (DMT) and its role in human consciousness, but we also welcome innovative...

Neurobehavioral and Molecular Pharmacology of Pharmahuasca ($\textit{N,N}$-dimethyltryptamine (DMT) and Harmine) in Humans – A Combined Neuropharmacological and Brain Imaging Approach

June 4, 2025 Klemens Egger

Over the past decade, research with psychedelics has gained new momentum, leading to a psychedelic renaissance in both basic and clinical research. Among these substances is ayahuasca, an Amazonian plant medicine used for millennia by indigenous people for ritualistic and healing practices, which has recently entered research labs in the Americas and Europe. Preliminary findings indicate its...

DOI: 10.5167/uzh-278132 (opens in new tab) Full text (opens in new tab) Neuroplasticity Psychedelic medicine Mental health treatment Brain imaging

Ayahuasca-inspired DMT/HAR formulation reduces brain differentiation between self and other faces.

Neuroimage June 1, 2025 Dila Suay, Helena Aicher, Micheal Kometer et al. 4 citations

Psychedelics are known to profoundly alter perception and self-referential processing, yet their specific effects on face recognition -particularly with regard to the recognition of face familiarity-remain underexplored. This study investigates the effects of an ayahuasca-inspired novel DMT/HAR (N,N-dimethyltryptamine/Harmine) formulation and Harmine alone on face recognition and...

Reducing Cardiovascular Side Effects of DMT Using Beta-Blockers.

ACS Medicinal Chemistry Letters May 8, 2025 Robert B. Kargbo 1 citation

DMT induces rapid antidepressant effects, but acute sympathomimetic side effects, particularly hypertension and tachycardia, limit its use. This study describes coformulations with short-acting beta-blockers or nitrates, matched to DMT's pharmacokinetics, to mitigate peripheral cardiovascular risks without compromising central therapeutic action, facilitating safer psychedelic therapy in...